ClinicalTrials.gg
CompletedNCT06940141Updated Sep 16, 2026

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

A Phase 2 interventional study of Rademikibart in prefilled syringe and Matching placebo in prefilled syringe in Asthma Acute, sponsored by Connect Biopharm LLC. Completed at 58 sites in 6 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
551st of 1,353
160 · median 100
Started
2025
with 36 others
Phase 2
292 of 1,695
22 open now
Registered
1,619th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 551st largest by enrollment of the 1,353 interventional ones that give a count, is one of 37 that started in 2025, is one of 292 in phase 2, and was the 1,619th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation

Read the detailed description

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, interventional trial in participants with an acute asthma exacerbation with type 2 inflammation to compare rademikibart plus standard therapy to standard therapy alone (plus placebo), targeting an acute asthma exacerbation in the urgent healthcare setting.

03

Conditions studied

  • Asthma Acute

Browse trials for

Keywords

  • Acute exacerbation
  • Asthma
  • Asthma exacerbation
  • CBP-201
  • Rademikibart
  • Connect Biopharma
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosed asthma with duration of ≥12 months.
  • Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication.
  • Must have experienced at least 1 asthma exacerbation requiring the use of systemic .
  • For participants in a stable condition, must have a documented historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb.
  • Current acute asthma exacerbation requiring an urgent healthcare visit for treatment.
  • Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation.
  • Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation.
  • ≥30% predicted.

Exclusion criteria

Exclusion Criteria:

  • Regular use of medication.
  • Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension.
  • Current or former smoker, has a smoking history including: If \<30 years old: Smoked for ≥5 pack-years; If ≥30 years old: Smoked for ≥10 pack-years
  • and other pulmonary disease other than asthma.
  • Known or suspected history of immunosuppression.
  • History of known immunodeficiency disorder or or C.
  • History of alcohol abuse and/or drug abuse.
  • Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy or other treated with apparent success with curative therapy.
  • Female participant who is pregnant, lactating or breast-feeding, or has a positive urinary β hCG test prior to randomization.
  • Recent receipt of any marketed nonbiologic drug that modulates type 2 cytokines (eg, suplatast tosilate).
  • Recent receipt of any marketed biologic drug or any biologic for asthma or other diseases.
  • Recent live, attenuated vaccinations or planned live, attenuated vaccinations during the trial.
  • Participants that have been recently treated with bronchial thermoplasty.
  • Recent treatment with systemic (ie, oral or by injection) and/or hospitalization for an exacerbation of asthma.
  • Recent receipt of any investigational nonbiologic drug.
  • A recent chest X-ray or computed tomography (CT) with findings that are inconsistent for an asthmatic population.

The above inclusion and exclusion criteria are not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Rademikibart

    Combination Product: Rademikibart in prefilled syringe

  • Placebo comparator
    Placebo

    Drug: Matching placebo in prefilled syringe

Interventions

  • Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.

    Also known as: CBP-201

  • DrugMatching placebo in prefilled syringe

    Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Treatment failure rate within 28 days after randomization

    Treatment failure is defined as death due to any cause, (re)admission to a hospital for asthma, ED (re)visit or unscheduled medical visit for worsening of asthma symptoms, or the necessity to intensify pharmacologic treatment (including second course of systemic steroids for asthma exacerbation) within 28 days after randomization.

    Time frame: 28 days

Secondary outcomes

  1. Absolute change from baseline (CFB) in post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at Week 1

    Time frame: Week 1

  2. Rate of new asthma exacerbations in the 28 days after randomization

    Time frame: 28 days

  3. Time to the first new asthma exacerbation in the 28 days after randomization

    Time frame: 28 days

  4. Mean CFB in morning/evening asthma symptom score

    Time frame: Week 1, Week 2, and Week 4

  5. Mean CFB in nocturnal awakenings (e-diary)

    Time frame: Week 1, Week 2, and Week 4

  6. Absolute CFB in post-BD FEV1

    Time frame: Day 3 and Week 4

  7. Incidence of adverse events (AEs), including serious adverse events (SAEs), adverse event of special interest (AESIs), and drug-induced liver injury (DILI) reported

    Time frame: 56 days

  8. Incidence of unanticipated adverse device effects (UADEs)

    Time frame: 56 days

  9. Incidence of injection site reactions

    Time frame: 56 days

07

Study locations

58 sites
  • Leland Stanford Junior University, Stanford Hospital
    Palo Alto, California 94304, United States
  • Amicis Research Center
    Valencia, California 91355, United States
  • Nemours Children's Hospital - DE
    Wilmington, Delaware 19803, United States
  • Nemours Children's Health
    Jacksonville, Florida 32207, United States
  • Pharmax Research of South Florida, Inc.
    Miami, Florida 33175, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33215, United States
  • Nemours Children's Health, Lake Nona
    Orlando, Florida 32827, United States
  • Health Synergy Clinical Research, LLC
    West Palm Beach, Florida 33407, United States
  • Primeway Clinical Research Group
    Fayetteville, Georgia 30214, United States
  • Pivotal Research Solutions
    Stonecrest, Georgia 30038, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Allergy & Asthma Specialists, P.S.C.
    Owensboro, Kentucky 42301, United States
  • Chesapeake Clinical Research, Inc.
    White Marsh, Maryland 21162, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Premier Pulmonary Critical Care and Sleep Medicine
    Denison, Texas 75020, United States
  • DCT- McAllen Primary Care Research, LLC dba Discovery Clinical Trials
    McAllen, Texas 78503, United States
  • Vermont Lung Center
    Colchester, Vermont 05446, United States
  • STAT Research
    Caba, Buenos Aires C1023, Argentina
  • Hospital Italiano de Buenos Aires
    Caba, Buenos Aires C1199, Argentina
  • Investigaciones en Alergias y Enfermoedades Respiratorias (InAER)
    Caba, Buenos Aires C1425BEN, Argentina
  • Instituto Ave Pulmo-Fundacion Enfisema
    Mar del Plata, Buenos Aires 7600, Argentina
  • Hospital Universitario Austral
    Pilar, Buenos Aires B1629ODT, Argentina
  • CEMER - Centro Medico de Enfermedades Respiratorias
    San Juan Bautista, Buenos Aires B1602, Argentina
  • Centro respiratorio Infantil
    Rosario, Santa Fe Province 2000, Argentina
  • INECO Neurociencias Oroño
    Rosario, Santa Fe Province S2000, Argentina
  • Investigaciones en Patologias Respiratorias SRL
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • INSARES
    Mendoza, 5500CCG, Argentina
  • Centro de Diagnostico y Rehabilitación S.A. -CEDIR
    Santa Fe, S3000, Argentina
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • St. Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • St George Hospital, South Eastern Sydney Local Health District
    Kogarah, New South Wales 2217, Australia
  • Queensland Children's Hospital
    South Brisbane, Queensland 4101, Australia
  • Bendigo Health
    Bendigo, Victoria 3550, Australia
  • JSC "National Center for Lung Health"
    Tbilisi, 0101, Georgia
  • LLC "Israel-Georgian Medical Research Clinic Healthycore"
    Tbilisi, 0112, Georgia
  • Acad. Chapidze Emergency Cardiology Center LLC
    Tbilisi, 0159, Georgia
  • Caucasus Medical Center
    Tbilisi, 0159, Georgia
  • LLC Diacor
    Tbilisi, 0159, Georgia
  • Raymann, LLC
    Tbilisi, 0186, Georgia
  • Clinical Hospital Center "Dragisa Misovic - Dedinje"
    Belgrade, 11040, Serbia
  • Clinical Hospital Center Zemun
    Belgrade, 11080, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Kamenitz, 21204, Serbia
  • University Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Institute for Pulmonary Diseases and Tuberculosis Nis
    Niš, 18108, Serbia
  • Health Center Uzice
    Užice, 31000, Serbia
  • Salford Royal Hospital - Northern Care Alliance NHS Foundation Trust Barnes Clinical Research Facility
    Salford, Greater Manchester M6 8HD, United Kingdom
  • Medicines Evaluation Unit Ltd.
    Wythenshawe, Greater Manchester M23 9QZ, United Kingdom
  • Norfolk and Norwich University Hospital NHS Foundation Trust
    Norwich, Norfolk NR4 7UY, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust of Trust Headquarters Queen Elizabeth hospital Birmingham
    Birmingham, B15 2GW, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • Bradford Teaching Hospitals NHS Foundation Trust
    Bradford, BD96RJ, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust
    London, SE1 7EH, United Kingdom
  • Kings College Hospital NHS Foundation
    London, SE5 9RS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jul 2026, 11 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 11 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 23, 2025
StartActual
Aug 8, 2025
Primary completionActual
Jul 17, 2026
CompletionActual
Aug 10, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06940141
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Aug 8, 2025
Primary completion
Jul 17, 2026
Completion
Aug 10, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion